Equities
TechnologySoftware & Computer Services
  • Price (USD)324.69
  • Today's Change0.44 / 0.14%
  • Shares traded332.36k
  • 1 Year change+158.41%
  • Beta1.5834
Data delayed at least 15 minutes, as of Sep 24 2021 21:10 BST.
More ▼
Take Survey
Help shape our future virtual events & community services
Take part in our survey for a chance to win a free 3-month standard gift subscription.

Profile data is unavailable for this security.

About the company

Gartner, Inc. (Gartner) is a research and advisory company. The Company is an advisor and objective resource for more than 14,000 organizations in more than 100 countries. Gartner creates and distributes its research content through published reports, interactive tools, facilitated peer networking, briefings, consulting and advisory services, and its conferences, including the Gartner Symposium/Xpo series. The Company’s segments include Research, Conferences and Consulting. The Research segment provides objective insights and advice on the mission-critical priorities of businesses across functional areas of an enterprise through research and other reports. Conferences segments provides business professionals across an organization the opportunity to learn, share and network. The Consulting segment provides fact-based consulting services to enable clients to use and manage information technology (IT).

  • Revenue in USD (TTM)4.38bn
  • Net income in USD571.91m
  • Incorporated1990
  • Employees15.60k
  • Location
    Gartner Inc56 Top Gallant RdPO Box 10212STAMFORD 06904-2212United StatesUSA
  • Phone+1 (203) 964-0096
  • Fax+1 (302) 636-5454
  • Websitehttps://www.gartner.com/en
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
10X Genomics Inc405.70m-504.02m17.09bn1.05k--21.76--42.14-4.72-4.723.807.080.521.689.85476,171.40-64.60---76.07--86.37---124.24--6.30-519.310.00--21.53---1,636.68------
Repligen Corporation508.51m99.93m17.77bn1.13k181.4111.08135.0834.951.781.789.1329.160.29412.046.72450,802.305.783.036.493.3558.8055.7319.6511.932.5511.810.1346--35.5334.39179.8845.0158.57--
Novavax, Inc.1.18bn-949.91m18.48bn791.00--24.71--15.64-13.71-13.7117.2210.040.642----1,494,221.00-51.60-58.17-104.56-78.78-----80.37-208.57---51.360.366--2,448.4867.33-215.21--24.49--
BIO-TECHNE Corp931.03m140.32m21.14bn2.60k155.3713.4393.0122.713.473.4722.9740.120.4342.716.95358,089.206.517.246.947.7067.9766.7514.9917.662.5918.280.178538.2426.0413.28-38.746.0821.260.00
Alnylam Pharmaceuticals, Inc.687.53m-886.68m22.27bn1.45k--26.04--32.39-7.60-7.605.897.200.19981.218.00473,182.40-25.76-35.41-29.83-40.1385.73---128.97-368.564.76-6.310.3367--124.2864.353.14--40.29--
ICON PLC3.19bn363.86m22.53bn16.48k41.457.3951.957.066.836.8359.8838.290.9906--3.23202,880.5011.3313.4117.5119.5028.4433.2511.4413.62--14.470.14720.00-0.304812.17-11.146.770.5273--
Charles River Laboratories Intl. Inc3.27bn396.08m23.10bn18.40k59.169.9635.497.067.757.7564.0546.010.547411.225.56177,905.606.706.687.837.9537.8737.2212.2410.581.155.540.5370.0011.5516.4944.5519.3821.37--
Catalent Inc4.00bn531.40m24.15bn17.30k45.466.1629.446.043.113.1123.5225.070.47355.633.82231,098.306.934.207.914.7833.8232.1414.638.331.945.770.43130.0029.2116.69205.7836.5337.50--
Horizon Therapeutics PLC2.56bn518.16m24.93bn1.70k49.266.1230.379.752.242.2411.1418.050.40123.794.001,832,756.008.131.349.501.6075.9467.8120.274.262.2510.060.38740.0069.2623.79-31.9858.0488.40--
AmerisourceBergen Corp.204.32bn-3.74bn25.41bn22.00k--669.17--0.1244-18.44-18.44988.120.18284.2214.7612.469,287,327.00-7.730.1172-28.720.48113.042.81-1.830.02550.562417.480.9456655.335.746.91-516.53--9.817.43
Gartner Inc4.38bn571.91m27.16bn15.60k50.0351.7834.366.206.496.4949.236.270.6256--3.99280,688.108.172.7213.384.7668.7963.3213.064.17--7.810.82360.00-3.4413.6414.348.7212.71--
Seagen Inc2.38bn597.27m29.35bn2.09k49.518.6544.5112.323.263.2613.0418.650.77932.237.121,139,333.0019.53-0.423122.12-0.48988.1690.3925.06-0.71686.77--0.00--137.3245.22486.81--43.82--
McKesson Corporation245.22bn-4.49bn31.42bn59.00k------0.1281-28.21-28.231,534.08-3.414.0712.7012.924,156,322.00-7.130.5468-23.871.615.155.37-1.750.1520.532317.731.01196.163.114.53-600.88---1.099.80
DuPont de Nemours Inc18.46bn1.28bn35.70bn34.00k31.141.339.961.932.199.9928.3351.230.32793.485.69542,911.802.330.05352.640.068834.5627.557.110.27671.993.860.279---5.18-16.00-308.73---20.45-25.30
Data as of Sep 24 2021. Currency figures normalised to Gartner Inc's reporting currency: US Dollar USD

Institutional shareholders

45.89%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 20218.92m10.66%
BAMCO, Inc.as of 30 Jun 20215.53m6.61%
Polen Capital Management LLCas of 30 Jun 20214.52m5.41%
BlackRock Fund Advisorsas of 30 Jun 20214.09m4.89%
Generation Investment Management LLPas of 30 Jun 20213.37m4.03%
SSgA Funds Management, Inc.as of 30 Jun 20213.25m3.88%
Fidelity Management & Research Co. LLCas of 30 Jun 20212.70m3.22%
Atlanta Capital Management Co. LLCas of 30 Jun 20212.60m3.11%
Harris Associates LPas of 30 Jun 20211.74m2.08%
Principal Global Investors LLCas of 30 Jun 20211.66m1.98%
More ▼
Data from 30 Jun 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
image